In the Superior Court of Pennsylvania - How Appealing

Attachments to Pa. Super. Ct. Brief for Appellants (hereinafter “Attachments”) at
186 (emphasis added).
The 1996 FDA–approved label for Prempro (the combined estrogen/progestin
pill (“E+P”) manufactured by Wyeth), issued when this drug was first marketed,
stated:
Breast cancer. Some studies have reported a moderately increased risk
of breast cancer (relative risk of 1.3 to 2.0) in those women on
estrogen replacement therapy taking higher doses, or in those
taking lower doses for prolonged periods of time, especially in
excess of 10 years. The majority of studies, however, have not
shown an association in women who have ever used estrogen
replacement therapy.
The effect of added progestins on the risk of breast cancer is
unknown, although a moderately increased risk in those taking
combination estrogen/progestin therapy has been reported. Other
studies have not shown this relationship. In a one year clinical
trial of Prempro * * *, 5 new cases of breast cancer were detected
among 1377 women who received the combination treatments * * *.
The overall incidence of breast cancer in this clinical trial does
not exceed that expected in the general population.
R.1682 (emphasis added).
The Prempro label contained its own beagle dog discussion with regard to
that medication’s progestin component:
Beagle dogs treated with MPA developed mammary nodules, some of
which were malignant. Although nodules occasionally appeared in
control animals, they were intermittent in nature, whereas the nodules
in the drug–treated animals were larger, more numerous, persistent,
and there were some breast malignancies with metastases. It is known
that progestogens stimulate synthesis and release of growth hormones
in dogs. The growth hormones, along with the progestogen, stimulates
mammary growth and tumors. In contrast, growth hormone in
humans is not increased, nor does growth hormone have any
significant mammotrophic role. Therefore, the MPA–induced
– 6 –